The KOR has emerged as an important therapeutic target because G protein biased KOR agonists are reported to possess analgesic activity without the liabilities of addiction and respiratory depression associated with conventional opioid analgesics which target the μ receptor21–24. The gene discussed is OPRK1; the disease is Respiratory insufficiency due to muscle weakness.